Ethotoin Use in Pediatric Seizure Patients
| Autor: | Barbara H. Korberly, Thomas J. Mrazik, Leonard J. Graziani |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Adult
Phenytoin Drug Adolescent business.industry Hydantoins medicine.medical_treatment media_common.quotation_subject medicine.disease Patient acceptance Phenytoin Sodium Ethotoin Anticonvulsant Seizures Child Preschool Anesthesia Pediatrics Perinatology and Child Health medicine Humans Phenobarbital Child business hirsutism medicine.drug media_common |
| Zdroj: | Archives of Pediatrics & Adolescent Medicine. 135:1139 |
| ISSN: | 1072-4710 |
| DOI: | 10.1001/archpedi.1981.02130360043015 |
| Popis: | Ethotoin (Peganone), 3-ethyl, 5-phenylhydantoin, reportedly had less anticonvulsant activity in epileptic patients than the two more commonly used anticonvulsants, phenytoin sodium and phenobarbital.1Phenytoin, an effective drug for treatment of generalized seizures other than absence, has several side effects, including gingival hyperplasia and hirsutism, which may reduce patient acceptance and compliance, especially in children and adolescents. Phenobarbital, with comparative anticonvulsant activity to phenytoin, is reported to cause behavioral disturbance, especially hyperactivity, in up to 42% of pediatric patients who receive the drug.2By contrast, ethotoin has minimal side effects,1but since its introduction in 1956 for the control of generalized seizures other than absence, it has not been studied extensively in epileptic children.3-5These previous studies did not report therapeutic blood levels for ethotoin, and the dosage that was used ranged from 500 mg to 5 g daily. In this communication, we review our experience with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|